Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) had its price target cut by Stifel Nicolaus from $108.00 to $100.00 in a research note published on Thursday morning. They currently have a buy rating on the pharmaceutical company’s stock. VRTX has been the topic of a number of other reports. RBC Capital Markets reaffirmed a buy rating on shares […]
